The effect of methyldopa and procainamide on suppressor cell activity in relation to red cell autoantibody production.
Kirtland et al (1980) suggested that methyldopa caused the production of red cell (RBC) autoantibodies by causing a persistent increase in lymphocyte cyclic AMP, which inhibited suppressor T cell function, leading to unregulated autoantibody production in some patients. They showed that significantly higher lymphocyte cyclic AMP concentrations were generated by lymphocytes from healthy donors after adding methyldopa, and by lymphocytes from patients who were receiving methyldopa compared to lymphocytes from healthy donors without methyldopa present. They also showed that methyldopa affected suppressor cell activity. We measured the effect of methyldopa and procainamide on suppressor cell activity, using a similar approach to Kirtland et al (1980). Suppressor cell activity was measured by measuring the amount of IgG, produced in vitro, by B cells following mitogen stimulation preceded by a 24 h incubation period. We found no significant increase in the amount of IgG generated by normal donor lymphocytes, when methyldopa or procainamide was present during the preincubation period. This is in contrast to the findings of Kirtland et al (1980). We also measured the amount of IgG generated in vitro by mitogen-stimulated lymphocytes from patients (with and without positive direct antiglobulin tests) taking methyldopa and compared this to the amount of IgG generated by lymphocytes from normal donors and patients (with and without positive direct antiglobulin tests). The results were similar for each group. This does not agree with the findings of Kirtland et al (1980) who found that lymphocytes from patients taking methyldopa produced more IgG in vitro than lymphocytes from normal donors. Our results do not support the hypothesis that methyldopa and procainamide induce autoantibodies by affecting suppressor cell function.
American Red Cross Blood Services, Southern California Region, Los Angeles 90006.
G
G
Garratty
P
P
Arndt
H E
HE
Prince
I A
IA
Shulman
D001323:Autoantibodies / Q000096:biosynthesis*; D001789:Blood Group Antigens / Q000276:immunology*; D002455:Cell Division / Q000187:drug effects; D002478:Cells, Cultured; D003298:Coombs Test; D006801:Humans; D007074:Immunoglobulin G / Q000096:biosynthesis; D007963:Leukocytes, Mononuclear / Q000187:drug effects; D008750:Methyldopa / Q000494:pharmacology*; D011342:Procainamide / Q000494:pharmacology*; D050378:T-Lymphocytes, Regulatory / Q000187:drug effects* / Q000276:immunology
D001323:Autoantibodies; D001789:Blood Group Antigens; D007074:Immunoglobulin G; D008750:Methyldopa; D011342:Procainamide